Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 10, 2017- Updated results of advanced RCC cohort from Study 111 support continued investigation of first-line use of the combination in ongoing Phase 3 CLEAR study
Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima® in the U.S. and...
-
Sep 10, 2017- Quality of life findings follow presentation of positive results at ASCO 2017 in which lenvatinib was the first systemic therapy to demonstrate non-inferiority to sorafenib in overall survival in first-line treatment of patients with unresectable HCC
Eisai Inc. announced today a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was observed in patients treated with lenvatinib as...
-
Aug 31, 2017- New data in metastatic renal cell carcinoma from Study 111 evaluating lenvatinib in combination with pembrolizumab to be presented in a proffered paper session on Saturday, Sept. 9 at 10:15 a.m. CEST
Eisai Inc. will present data from its lenvatinib (marketed as Lenvima®) clinical trial program in four difficult-to-treat cancers at the European Society of Medical Oncology (ESMO) 2017 Congress...
-
Aug 28, 2017First kinase inhibitor to show improvement in overall survival in any patient group with RAI-R DTC
Eisai Inc. announced data from a prespecified subgroup analysis, which was published in the Journal of Clinical Oncology, showing treatment with lenvatinib (marketed as Lenvima®) resulted in a...
-
Jul 26, 2017- First antiepileptic drug (AED) to apply FDA's regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to patients sooner
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for FYCOMPA® (perampanel) CIII as monotherapy use...
-
Jul 25, 2017- Filing based on positive pivotal Phase 3 trial demonstrating non-inferior overall survival compared to sorafenib
Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the first-line use of lenvatinib (marketed as Lenvima®), the...
-
Jul 17, 2017
Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International...
-
Jun 21, 2017Lorcaserin Phase IIIb/IV Outcomes Study Assesses Incidence of Major Adverse Cardiovascular Events (MACE) in Patients with Overweight or Obesity
Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as planned, based on the recommendation of an independent...
-
Jun 4, 2017- Lenvatinib is the first systemic therapy to demonstrate non-inferiority to sorafenib in the primary efficacy endpoint of overall survival
Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple receptor tyrosine kinase inhibitor...
-
Jun 3, 2017- Interim results of first evaluable cohort (metastatic endometrial cancer) of Study 111, the Phase 1b/2 trial evaluating lenvatinib in combination with pembrolizumab in selected solid tumors, to be presented at 2017 ASCO Annual Meeting
Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...